The goal of early-phase clinical development – Phase I through IIa – is to test for the safety and efficacy of a drug candidate. In any disease state, conducting successful early phase trials is a key component of ushering a novel therapy through clinical development. Clinical Ink’s integrated SureSource® platform streamlines clinical development – from start to submit — to dramatically reduce R&D costs and project timelines while improving data quality and patient safety.
